within Pharmacolibrary.Drugs.ATC.M;

model M09AX13
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 5.1 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,
    adminCount     = 1,
    Vd             = 0.00020999999999999998,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Casimersen is an antisense oligonucleotide used for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping. It is approved by the FDA and marketed under the brand name Amondys 45.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated from FDA label and public summaries for intravenous administration in male pediatric patients (ages 7–20 years) with Duchenne muscular dystrophy.</p><h4>References</h4><ol><li><p>Goey, AKL, et al., &amp; East, L (2024). Characterization of Nonclinical Drug Metabolism and Pharmacokinetic Properties of Phosphorodiamidate Morpholino Oligonucleotides, a Novel Drug Class for Duchenne Muscular Dystrophy. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 52(12) 1396–1406. DOI:<a href=&quot;https://doi.org/10.1124/dmd.124.001819&quot;>10.1124/dmd.124.001819</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39516029/&quot;>https://pubmed.ncbi.nlm.nih.gov/39516029</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M09AX13;
